# Synergistic killing of bacterial pathogens by histones > **NIH NIH R56** · UNIVERSITY OF CALIFORNIA-IRVINE · 2021 · $441,663 ## Abstract Project Summary/Abstract The effective treatment of bacterial infections of skin, deep soft tissues and wounds continues to be a major unmet challenge in healthcare settings, especially among patients with chronic diabetes. Staphylococcus aureus and Pseudomonas aeruginosa are the most common bacteria that are isolated from chronic, non- healing wounds. Antibiotic resistance has arisen in these particular bacteria, causing these infections to become increasingly difficult to treat and giving rise to multi-drug resistant strains, including Methicillin-resistant Staphylococcus aureus (MRSA). The goal of the proposed work is to develop the next generation of therapeutics for which the design is inspired by a better mechanistic understanding of mammalian antimicrobial defense pathways. We focus our attention on the antimicrobial activities of neutrophil extracellular traps (NETs) and lipid droplet (LDs), which use histones to kill or suppress fungal and bacterial proliferation. The antimicrobial mechanism of histones has not been understood. The Siryaporn and Gross labs recently reported that the pairing of histones with an additional component found in NETs and LDs – the antimicrobial peptide (AMP) LL-37 (cathelicidin) – produces potent antimicrobial synergy. LL-37 forms pores in the bacterial membrane, which enable histones to enter the bacterium and interfere with gene expression. This has an irreversible bactericidal (killing) effect on bacteria. The work proposed here will exploit this discovery by identifying combinations of human histones and pore-forming antimicrobial agents that produce potent antimicrobial activity and synergy. The overall objective of the project is to better understand the mechanism of antimicrobial synergy between histones and pore- forming agents, and to harness it to create a class of new therapeutics for the treatment of skin infections and wounds. We will accomplish this objective by identifying combinations of human histones with LL-37 and other pore-forming antimicrobials that produce the greatest antimicrobial activities and synergies. We will test these against S. aureus, P. aeruginosa, and communities of skin bacteria in vitro (Aim 1). We will attempt to augment the antimicrobial activity by engineering in factors that impact histone function in NET and LDs, specifically chemical modification through citrullination and spatial localization to structures (Aim 2). To bring the strategy closer to the clinic, we will test the combinations of histones and pore-forming antimicrobials identified in Aims 1 and 2 in a standardized mouse skin infection model (Aim 3). To additionally address the unmet challenge of treating skin infection and wounds in diabetes patients, we will perform the tests in a diabetic mouse model. The results of this work will provide a mechanistic understanding of antimicrobial synergy and develop a strategy to combat the rise of antibiotic resistance. The results of the study could create a ne... ## Key facts - **NIH application ID:** 10457612 - **Project number:** 1R56AI163196-01 - **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE - **Principal Investigator:** Albert Siryaporn - **Activity code:** R56 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $441,663 - **Award type:** 1 - **Project period:** 2021-08-24 → 2022-07-11 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10457612 ## Citation > US National Institutes of Health, RePORTER application 10457612, Synergistic killing of bacterial pathogens by histones (1R56AI163196-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10457612. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*